Distinguishing a stress-triggered cardiac event from a true heart attack in the emergency setting has historically required invasive angiography — a time-consuming, resource-intensive procedure with its own procedural risks. A new diagnostic tool may substantially change that calculus, offering clinicians a blood-based triage option before the catheter lab is ever involved.
The BioTAK score was developed and validated across 3,615 patients drawn from overlapping registries, including 146 confirmed Takotsubo syndrome (TTS) cases and over 3,400 acute coronary syndrome (ACS) patients. Using machine learning-guided feature selection followed by logistic regression, researchers identified five variables that collectively discriminate TTS from ACS with excellent accuracy prior to invasive coronary angiography. The final model incorporates N-terminal pro-B-type natriuretic peptide (a myocardial stress marker), peptidylglycine α-amidating monooxygenase (linked to vasoconstriction and anxiety signaling), soluble lectin-like oxidized LDL receptor-1 (a marker of atherosclerotic plaque instability), LDL cholesterol, and patient sex. External validation in an independent cohort of 1,792 patients confirmed strong discriminative performance.
The clinical significance here is considerable. TTS, often called "broken heart syndrome," is disproportionately prevalent in postmenopausal women and carries a mortality risk that rivals ACS in the acute phase, yet its management diverges sharply. Misclassification in either direction carries real harm: TTS patients unnecessarily exposed to thrombolytics or anticoagulation, or ACS patients denied timely revascularization. The inclusion of a neurohormonal anxiolytic pathway biomarker — PAM — is particularly noteworthy, as it points toward the catecholamine-surge hypothesis and may reflect the psychoneuroendocrine signature distinguishing TTS. That said, the absolute TTS case count remains small relative to the ACS comparator group, which can inflate apparent discrimination metrics. Real-world emergency deployment will also require rapid, standardized assay availability for all five components. This work is best characterized as a strong proof-of-concept requiring prospective clinical utility trials before guideline integration.